Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0T using high-relaxivity contrast agents

Acta Radiologica

Volumn 51, Issue 1, 2010, Pages 78-84

  Huang, Biao ^a,b   Liang, Chang Hong ^a   Liu, Hong Jun ^a   Wang, Guang Yi ^a   Zhang, Shui Xing ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NONE   (China)

Author keywords

Comparative study; Detection; Magnetic resonance imaging; Metastasis

Indexed keywords

BODY WEIGHT; BRAIN LESIONS; BRAIN METASTASIS; COMPARATIVE STUDIES; COMPARATIVE STUDY; CONTRAST AGENT; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; CONTRAST-ENHANCED; GD-DTPA; IN-VIVO; LOW DOSE; RANK TEST; RELAXIVITY; WHITE MATTER;

BRAIN; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; PATHOLOGY;

GADOLINIUM;

CONTRAST MEDIUM; DRUG DERIVATIVE; GADOBENIC ACID; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

AGED; ARTICLE; BRAIN TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; FEMALE; HUMAN; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; STATISTICS, NONPARAMETRIC;

EID: 75649144973     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.3109/02841850903350178     Document Type: Article

References (21)

1. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44:275-281
2. Akeson P, Larsson EM, Kristoffersen DT, Jonsson E, Holtas S. Brain metastases-comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995;36:300-306
3. Haustein J, Laniado M, Niendorf HP, Louton T, Beck W, Planitzer J, et al. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 1993;186:855-860
4. Sze G, Johnson C, Kawamura Y, Goldberg SN, Lange R, Friedland RJ, et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. Am J Neuroradiol 1998;19:821-828
5. Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of highdose gadoteridol. J Magn Reson Imaging 1994;4:669-673
6. Wintersperger BJ, Runge VM, Biswas J, Reiser MF, Schoenberg SO. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol 2007;42:558-563
7. Biswas J, Nelson CB, Runge VM, Wintersperger BJ, Baumann SS, Jackson CB, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-tonoise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol 2005;40:792-797
8. Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
9. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809.
10. Baleriaux D, Colosimo C, Ruscalleda J, Korves M, Schneider G, Bohndorf K, et al. Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 2002;44:191-203.
11. Vecht CJ. Clinical management of brain metastasis. J Neurol 1998;245:127-131
12. Takeda T, Takeda A, Nagaoka T, Kunieda E, Takemasa K, Watanabe M, et al. Gadolinium-enhanced three-dimensional magnetization-prepared rapid gradient-echo (3D MP-RAGE) imaging is superior to spin-echo imaging in delineating brain metastases. Acta Radiol 2008;49: 1167-1173
13. Essig M. MR imaging of CNS tumors: are all contrast agents created the same? Neuroradiology 2006;48 Suppl 1:3-8.
14. Bleicher AG, Kanal E. A serial dilution study of gadolinium- based MR imaging contrast agents. Am J Neuroradiol 2008;29:668-673
15. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic fi eld strengths. Invest Radiol 2005;40:715-724
16. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213-21. Erratum in Invest Radiol 2006;41:859.
17. Krautmacher C, Willinek WA, Tschampa HJ, Born M, Traber F, Gieseke J, et al. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T-initial experience. Radiology 2005;237:1014-1019
18. Runge VM, Biswas J, Wintersperger BJ, Baumann SS, Jackson CB, Herborn CU, et al. The Efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol 2006;41:244-248
19. Rumboldt Z, Rowley HA, Steinberg F, Maldjian JA, Ruscalleda J, Gustafsson L, et al. Multicenter, doubleblind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760-767
20. Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. Am J Neuroradiol 1995;16:373-380
21. Brekenfeld C, Foert E, Hundt W, Kenn W, Lodeann KP, Gehl HB. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T. Invest Radiol 2001;36:266-75.